a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

Inclusion Criteria

• •1. Signed written informed consent
• •2. Diagnose as Relapsed and Refractory B -ALL, and meet one of the following conditions:
• •1. Failed to standard chemotherapy regimens;
• •2. Relapse after complete remission, high-risk and / or refractory patients ;
• •3. Relapse after hematopoietic stem cell transplantation;
• •3. For patients with Ph + ALL, the following conditions must be met: those who have received a standard induction chemotherapy regimen and who have not achieved complete remission after TKI treatment or have relapsed after remission (cannot tolerate TKI treatment or have contraindications to TKI treatment or the presence of TKI class) Except for drug resistant patients)
• •4. Evidence for cell membrane CD19 or CD22 expression
• •5. All genders ages: 2 to 75 years
• •6. The expect time of survive is above 3 months;
• •7. KPS\>60
• •8. No serious mental disorders ;
• •9. Left ventricular ejection fraction ≥50%
• •10. Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN;
• •11. Sufficient renal function defined by creatinine clearance≤2 x ULN;
• •12. Sufficient pulmonary function defined by indoor oxygen saturation≥92%;
• •13. With single or venous blood collection standards, and no other cell collection contraindications;
• •14. Ability and willingness to adhere to the study visit schedule and all protocol requirements.